Donate to IPJC!


World Health Statistics 2015

Aug 25
Shareholder Resolution Challenges Walgreens on Continued Sales of Tobacco

Aug 25
Tyson Foods' Investors Question Company's ESG Record via Shareholder Resolutions for the 2017 Proxy Ballot

April 12
More than 50 Health, Religious, & Labor Groups Urge Congress to Reject TPP Trade Deal

Principles & Recommended Corporate Practices to Promote Global Health

Principles & Recommended Practices for Corporations on Domestic Health Issues

NW Coalition for
Responsible Investment


Issues Home

Northwest Coalition for Responsible InvestmentS

Access to Health

Domestic Health─Achieve universal access to quality affordable health care

Since the Affordable Care Act went into effect in 2013, ICCR & NWCRI members have focused on ensuring its implementation among employers, medical device and pharmaceutical manufacturers, and insurance companies. Our goal is to increase the number of people that have health insurance and to bend the “cost curve” for health care so that it is more affordable.

Global Health─Advocate for access to health as a human right and the responsibility of pharmaceutical companies to increase access to medicines and services in vulnerable communities.

An important tool for our global health work is the 2014 Access to Medicine Index. This resource ranks 20 pharmaceutical companies on how they promote universal access to essential medicines to people living in the 106 countries with low or medium levels of development. While significant milestones for improving access to medicine have been achieved, there is still no sustainable model for ensuring that the poorest people have access to the medicines they need.

NWCRI leads the dialogues with Merck and Gilead Sciences, which rank seventh and fifth respectively in the Index.

Good News for Children Living with HIV
The Medicines Patent Pool (MPP) was established in 2010 with the goal of increasing access to HIV/AIDS medicines through the sharing of licenses by major pharmaceutical companies with generic manufacturers. Gilead Sciences was the only member until 2013. Now HIV/AIDS formulations have been added by Bristol-Myers Squibb, Roche, AbbVie, Merck, ViiV and Johnson & Johnson (Janssen). The licenses from the latter four companies are for HIV/AIDs medicines for children in low and middle income countries where 98% of children with HIV live. Of the 3.2 million children worldwide living with HIV only 550,000 have access to medicines. Without treatment 50% die by age two and 80% by age five.